In this episode of the Journal of Gynecologic Oncology podcast, we explore a recent study by Nishimura and colleagues that examines the role of platinum-based chemotherapy in patients with intermediate-risk early-stage cervical cancer. The study identifies high-risk subgroups within the intermediate-risk population—those with multiple risk factors such as large tumor size, lymphovascular space invasion, and deep stromal invasion—and evaluates the impact of adjuvant chemotherapy on recurrence-free survival. The results highlight the significant benefit of chemotherapy in preventing recurrence for high-risk patients, while low-risk patients demonstrated excellent outcomes with no further therapy. Tune in to learn more about how this research could help personalize treatment strategies for cervical cancer.

Comparison of postoperative adjuvant platinum-based chemotherapy and no further therapy after radical surgery in intermediate-risk early-stage cervical cancer (https://doi.org/10.3802/jgo.2025.36.e2)